American Society of Hirudotherapy

Non-anticoagulant factors affecting coagulation in the extracorporeal circulation circuit and the development of an individualized regional citrate anticoagulation protocol for hemodialysis: A real-world retrospective study

Research article published in The International journal of artificial organs (2023)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Research reportClinical LiteratureHu et al. · The International journal of artificial organs, 2023

Abstract

OBJECTIVE: To investigate non-anticoagulant factors that affect blood coagulation in the extracorporeal circulation (ECC) circuit of regional citrate anticoagulation (RCA) protocol for hemodialysis (HD). METHOD: The clinical characteristics of patients undergoing an individualized RCA protocol for HD between February 2021 and March 2022 were collected; Coagulation scores, pressures in various parts of the ECC circuit, the incidence of coagulation, and citrate concentrations in the ECC circuit during treatment were determined, and non-anticoagulant factors affecting coagulation in the ECC circuit were analyzed. RESULT: The lowest clotting rate was 2.8% in patients with arteriovenous fistula in various vascular access. Patients on Fresenius dialysis had a lower rate of clotting in the cardiopulmonary bypass line than patients on other brands of dialyzer. Low-throughput dialyzers are less likely to clot than high-throughput dialyzers. There are significant differences in the incidence of coagulation among different nurses during citrate anticoagulant hemodialysis. CONCLUSION: In the process of citrate anticoagulant hemodialysis, non-anticoagulant factors such as coagulation status, vascular access, dialyzer selection, and operator quality will affect the anticoagulant effect.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsHumansCitric AcidAnticoagulantsRetrospective StudiesRenal DialysisBlood CoagulationCitratesExtracorporeal Circulation

Summary

In patients on individualized regional citrate anticoagulation for hemodialysis, clotting rates varied with vascular access, dialyzer brand and throughput, and operator, with the lowest clotting rate (2.8%) seen with arteriovenous fistula access.

Context

This study examined non-anticoagulant factors influencing blood coagulation in extracorporeal circulation circuits during regional citrate anticoagulation hemodialysis, analyzing coagulation scores, circuit pressures, and clotting incidence in patients treated between February 2021 and March 2022. The investigators reported a lowest clotting rate of 2.8% among patients with arteriovenous fistulas, lower clotting with Fresenius dialyzers versus other brands and with low-throughput versus high-throughput dialyzers, and significant variation in coagulation incidence among different nurses. For hirudotherapy, this work is relevant because it demonstrates that anticoagulant effectiveness depends substantially on non-pharmacologic variables—vascular access, equipment selection, and operator technique—a principle worth considering when evaluating real-world outcomes of leech-derived anticoagulants such as hirudin. An honest caveat is that this study investigated citrate anticoagulation in hemodialysis circuits, not hirudin or leech therapy directly, and it does not establish causal relationships among the factors identified.

Citation

Reference (Vancouver style)

Hu Z, Xu J, Gong Y, Gan C, Jiang T, Wu X, et al. Non-anticoagulant factors affecting coagulation in the extracorporeal circulation circuit and the development of an individualized regional citrate anticoagulation protocol for hemodialysis: A real-world retrospective study. Int J Artif Organs. 2023;46(6):329-336. doi:10.1177/03913988231168162. PMID: 37278534

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.